Clinical trials: Solid Tumors (Phase 1)
Solid Tumor
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
This is an open, multi-center, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics and initial efficacy of FTL001 in patients with advanced and metastatic solid tumors.
- Trial name
- NCT06410092
- Testing
- FTL001
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- Sound Biopharmaceuticals Ltd.
Cancer
A Study of TAVO412 in Patients with Cancer
TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412.
- Trial name
- TAVO412 (NCT05548634)
- Testing
- TAVO412
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Tavotek Biotherapeutics
Solid Tumors
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized.
- Trial name
- NCT00778128
- Testing
- CP-4126, Gemcitabine
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 26 people
- Sponsor
- Clavis Pharma
Advanced Solid Tumor
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05684965
- Testing
- XTX301
- Where
- 12 sites in United States
- Volunteers
- 358 people
- Sponsor
- Xilio Development, Inc.
Neoplasm Metastasis
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03383692
- Testing
- DS-8201a, Ritonavir, Itraconazole
- Where
- 10 sites in Japan, South Korea and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Solid Malignancies
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
- Trial name
- NCT00162136
- Testing
- Ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- R-Pharm
Advanced Solid Tumor
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
In this study, MEK162 will be administered to Japanese patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01469130
- Testing
- MEK162
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Evaluation of BL-M07D1 for injection in Phase I clinical study of safety, tolerability, pharmacokinetic Characteristics, and initial efficacy in patients with locally advanced or metastatic digestive tract tumors and other solid…
- Trial name
- NCT05631964
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor
Study of AK119 in Subjects With Advanced Solid Tumors
This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05173792
- Testing
- AK119
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Akeso
Solid Tumor Malignancies, EGFR Positive Solid Tumors
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in…
- Conditions
- Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
- Trial name
- NCT06960395
- Testing
- VIR-5525, Pembrolizumab
- Where
- 4 sites in United States, Australia
- Volunteers
- 450 people
- Sponsor
- Vir Biotechnology, Inc.
Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC)
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- Trial name
- STAR (NCT06895031)
- Testing
- JYP0015
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Solid Tumor
A Study of LY3200882 in Participants With Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
- Trial name
- NCT02937272
- Testing
- LY3200882, LY3300054, Gemcitabine
- Where
- 18 sites in United States, Australia and 6 more
- Volunteers
- 223 people
- Sponsor
- Eli Lilly and Company
Hematological Malignancies, Leukemia
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors
- Trial name
- NCT00088101
- Testing
- STA-5312
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Synta Pharmaceuticals Corp.
Advanced Or Metastatic Solid Tumor Malignancies
A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
This is a first in human, open-label, single-arm, multicenter dose escalation and expansion Phase 1 study of SHR-A2102 in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05735275
- Testing
- SHR-A2102
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
This is a Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BAT4706 Injection Combined With BAT1308 Injection in Patients With Advanced Solid Tumors.
- Trial name
- NCT06139536
- Testing
- BAT4706 Injection, BAT1308 Injection
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- Bio-Thera Solutions
Solid Tumors
Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib administered orally over a range of doses in patients with advanced solid tumors.
- Trial name
- NCT02122809
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Advanced Solid Tumors, Pancreatic Carcinoma
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies.
- Conditions
- Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
- Trial name
- NCT06799637
- Testing
- XNW28012
- Where
- 24 sites in China
- Volunteers
- 350 people
- Sponsor
- Evopoint Biosciences Inc.
Advanced Solid Tumors
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
- Trial name
- NCT05625412
- Testing
- BMS-986360, Docetaxel, Nivolumab
- Where
- 35 sites in United States, Argentina and 7 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignant Tumour
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour.
- Trial name
- NCT06383871
- Testing
- HRS-7058 capsule/ HRS-7058 tablet
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.